Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion

Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease

(2014) Christine Bernsmeier et al.   PLoS One

The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

(2013) Zun Xiang et al.   BMC GASTROENTEROLOGY

Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

(2013) Maria Stepanova et al.   DIGESTIVE DISEASES AND SCIENCES

Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review

(2013) Manhal Olaywi et al.   Hepatobiliary & Pancreatic Diseases International

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

(2012) Luciano Adorini et al.   DRUG DISCOVERY TODAY

The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

(2012) Naga Chalasani et al.   GASTROENTEROLOGY

Specific bile acids inhibit hepatic fatty acid uptake in mice

(2012) Biao Nie et al.   HEPATOLOGY

FXR signaling in the enterohepatic system

(2012) Tsutomu Matsubara et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

The Bile Acid Membrane Receptor TGR5: A Valuable Metabolic Target

(2011) Thijs W.H. Pols et al.   DIGESTIVE DISEASES

Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet–fed KK-Ay mice

(2011) Takuma Tsuchida et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Tauroursodeoxycholic Acid May Improve Liver and Muscle but Not Adipose Tissue Insulin Sensitivity in Obese Men and Women

(2010) Marleen Kars et al.   DIABETES

Bile Acids as Regulators of Hepatic Lipid and Glucose Metabolism

(2010) Michael Trauner et al.   DIGESTIVE DISEASES

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

(2010) Nitika Arora Gupta et al.   HEPATOLOGY

The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation

(2010) Thijs W.H. Pols et al.   JOURNAL OF HEPATOLOGY

Effects of feeding bile acids and a bile acid sequestrant on hepatic bile acid composition in mice

(2010) Youcai Zhang et al.   JOURNAL OF LIPID RESEARCH

Liver disease: an overlooked complication of diabetes mellitus

(2010) Marco Arrese   Nature Reviews Endocrinology

Changes in Hepatic Gene Expression upon Oral Administration of Taurine-Conjugated Ursodeoxycholic Acid in ob/ob Mice

(2010) Jae-Seong Yang et al.   PLoS One

Fatty liver and lipotoxicity

(2009) Michael Trauner et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats

(2009) Sabrina Cipriani et al.   JOURNAL OF LIPID RESEARCH

Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation

(2009) Philippe Lefebvre et al.   PHYSIOLOGICAL REVIEWS

Targeting bile-acid signalling for metabolic diseases

(2008) Charles Thomas et al.   NATURE REVIEWS DRUG DISCOVERY

Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-α and macrophage inflammatory protein-2 production

(2007) Kaoru Ishizaki et al.   EUROPEAN JOURNAL OF PHARMACOLOGY